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Introduction
Clonal hematopoiesis of indeterminate potential (CHIP) has been defined as somatic mutations in the peripheral blood at variant allele fractions (VAF) >0.02 in individuals without evidence of hematologic malignancy 1 . The threshold of 0.02 VAF was arbitrarily derived, reflecting the technical limitations of the standard next generation sequencing (NGS) and not biologic risk of leukemic transformation with lower frequency mutations. To date, there have been no systematic screening recommendations for identifying or surveilling CHIP in healthy individuals. Nonetheless, the presence of CHIP has been shown to increase the risk of developing hematologic malignancy (in aggregate) by 0.5-1% per year 2,3 , although the absolute risk of leukemic transformation in individuals with CHIP is very low. Recently, two studies demonstrated an increased risk of developing AML in individuals with CHIP detected using targeted sequencing of peripheral blood samples collected several years prior to diagnosis 4, 5 .
Independently, error-corrected sequencing (ECS) has enabled accurate interrogation of the hematologic somatic mutational profile at VAFs ≥ 0.0001 6 and demonstrated that selection of pre-existing clones can lead to therapy-related leukemia 7 . Our ECS-based study of blood samples collected approximately 10 years apart from 20 adult women without AML revealed that nearly all studied individuals harbored somatic mutations frequently observed in myeloid malignancies. The detected hematopoietic clones were often stable over the 10 years between blood collections and did not demonstrate positive selection or clonal expansion, regardless of the gene mutated. It is important to note that clonal mutations at a lower frequency than 0.02 VAF are currently not regarded as CHIP, and their clinical significance is even less well understood. The two aforementioned studies of pre-diagnosis CHIP observed associations of increased AML risk for persons with clones ≥ 0.005 or ≥ 0.01 VAF over a shorter follow-up period 4, 5 . The present investigation examined whether detection of lower-VAF clones or specific mutations are associated with future risk of AML in a nested case-control sample (35 cases, 70 controls) from the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts with up to 22 years of follow-up after sample collection 8, 9 . We also investigated whether clonal evolution over 10 years was associated with long-term future risk of AML in 11 women in the NHS with multiple pre-diagnosis samples.
Results
Study Samples
Due to the matched design, the cases and controls had similar distributions of sex, age at blood collection and interval from blood draw to case diagnosis or control index date ( Table 1 ). The median age of sample collection was 61 years for the first collection and 70 years for the second collection. The median age of AML diagnosis was 76 years (range 53-87 years). More than 90% of cases and controls had one year or more of follow-up after blood draw, and >88% of each group had follow-up intervals of five or more years. All the women with repeat blood samples had at least one year of follow-up after the second blood collection ( Table  1 ). All the participants selected into the study sample had self-reported their race/ethnicity as White.
Error-Corrected Sequencing Results
During ECS library preparation, we generated an average of 60 million raw sequenced reads, yielding 3.9 million ECS reads, per library, which translated into approximately 8,000x ECS read coverage of the target space. We identified 563 single nucleotide variants and 35 insertion/deletion (indel) variants by ECS; this corresponded to detection of AML-associated mutations in 97% of all participants (598 mutations, 5.8/person), with an average of 7.4 (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] per case and an average of 5.0 (range 0-15) per control (Supplementary Table 2 ). As expected, due to the targeted enrichment sequencing scheme, these mutations predominantly occurred in exonic regions (Supplementary Figure 1A) . Most detected mutations were predicted to change the underlying amino acid sequence in cases and controls (Supplementary Figure 1B) . Of the 252 clonal mutations detected in the cases, we identified 144 nonsynonymous SNVs (57%), 40 stop gain variants (16%), 22 intronic variants (9%), 18 indels (7%), 12 synonymous SNVs (5%), 11 splice variants (4%), 4 UTR variants (2%), and 1 stop loss variant (<1%). Of the 346 clonal mutations detected in the matched controls, we identified 208 nonsynonymous SNVs (60%), 47 intronic variants (14%), 34 synonymous SNVs (10%), 30 stop gain variants (9%), 13 indels (4%), 12 splice variants (3%), and 2 UTR variants (<1%). As expected, C to T (G to A) substitutions were by far the most common in both cases and controls (Supplementary Figure 1C) .
Droplet Digital PCR Validation
Spearman correlation coefficients reflect a high correspondence between ECS and ddPCR variant calls at both blood collections (collection 1, r=0.97, p<0.0001; collection 2, r=0.95, p<0.0001 Supplementary Figure 2 and Supplementary Table 3 ).
Gene-Specific Mutations
As expected, the most frequently observed mutations occurred in the epigenetic regulators DNMT3A and TET2, although we observed mutations in most of the genes targeted by the assay (Figure 1 and Supplementary Figure 3 ). In cases, we observed 58 DNMT3A and 56 TET2 clonal variants, comprising 23% and 22% of the 252 clonal variants detected in cases, respectively. In controls, we observed 128 DNMT3A and 57 TET2 clonal mutations, comprising 37% and 16% of the 346 clonal mutations detected in controls, respectively. Most mutations occurred in exonic regions and were predominantly nonsynonymous and nonsense mutations ( Supplementary Figure 3) . The observed exonic variants in DNMT3A occurred predominantly in the functional domains (Supplementary Figure 4A) . The observed exonic variants in TET2 occurred across the entire amino acid sequence (Supplementary Figure 4B ). No single mutation in TET2 was observed in more than two individuals.
Association of Individual Variants and Clonal Hematopoiesis with AML risk.
For the mutations that occurred in at least four individuals, associations with AML were similar in magnitude whether we classified mutation status according to the first or according to either blood collection (Table 2) . Thus, for brevity, we focus herein on the findings based on either blood collection. Detecting the DNMT3A R822H variant at either time point was associated with a 14-fold increased risk of AML (OR: 14.0, 95%-CI: 1.7-113.8; p=0.01). Participants with either a DNMT3A R882H or R882C variant ("R882H/C") at either collection had a more than seven-fold increased risk of AML relative to individuals without either variant (OR: 7.3, 95%-CI: 1.5-34.7; p=0.01). For the DNMT3A W860R and ASXL1 E1183K variants, the sparse counts prevented estimation of 95% CIs by the conditional logistic regression models (implying a 95% CI range from zero to infinity). The JAK2 V617F variant, which we observed only in men in the present study sample, had a nonsignificant positive association with future development of AML (Table 2) .
Individuals with clonal mutations detected at ≥ 0.01 (OR: 5.4, 95% CI: 1.8-16.6; p=0.003) or ≥ 0.02 VAF (OR: 5.6, 95% CI: 1.8-17.2; p=0.003) had a significantly increased risk of AML compared to those without a mutation detected at or above those thresholds ( Table 2 ). The association with AML risk for VAFs lower than 0.01 was unclear; for example, individuals with mutations at a VAF of ≥ 0.005 at either blood collection had a 2.5-fold increase in AML risk that was not statistically significant (OR: 2.5, 95% CI: 1.0-6.3; p=0.05). Further, nearly every case and most controls had at least one clonal mutation at ≥ 0.001 VAF. Of interest, the ASXL1 E1183K variant noted above, which we observed in five women (4 cases, 1 control) and for which an association with AML risk could not be well quantified due to sparse counts, occurred at VAFs between 0.001 and 0.002.
Sensitivity analyses that omitted records for the cases and controls with less than one year of follow-up after blood collection did not materially change the main findings. One omitted case and two omitted controls were positive for DNMT3A R882H/C, whereas the remaining omitted case and four omitted controls were negative for that variant. Even after omitting these participants, detecting the DNMT3A R882H/C variant at one or both blood collections remained a statistically significant risk factor for AML (OR: 14.0, 95% CI: 1.7-113.8; p=0.01), as did detecting any mutation with a VAF ≥ 0.01 (OR: 5.1, 95% CI: 1.6-15.9; p=0.005) or ≥ 0.02 (OR: 5.3, 95% CI: 1.7-16.4; p=0.004).
In the exploratory analyses restricted to AML cases, we did not observe marked differences in time to AML diagnosis by DNMT3A R882H/C mutation status (detected vs. not detected) or by detection of any mutation at VAFs of 
Clonal stability
We examined clonal evolution of mutations over time in 11 matched sets of women (NHS) with samples banked approximately 10 years apart ( Figure 2A ). The VAF of mutations detected in these cases at blood collection one (median 0.0021, range 0.0003-0.0782) and blood collection two (median 0.0037, range 0.0006-0.2992) was very similar to controls at collection one (median 0.0017, range 0.0003-0.0731) and collection two (median 0.0023, range 0.0003-0.2689). In the cases with two blood collections, 31 clonal mutations occurred only at the first blood draw, 37 occurred only at the second blood draw, and 22 occurred at both time points (yellow data points connected with a line on Figure 2A ). Of the latter 22 clonal mutations, in the ~10 years between the first and second blood draw, five (23%) increased by >0.01 VAF, none decreased by >0.01 VAF, and 17 (77%) were unchanged. In controls with two blood collections, 27 clonal mutations occurred only at the first blood draw, 58 only at the second blood draw, and 29 at both time points (blue and red data points connected by lines in Figure 2A ). Of the latter 29 clonal mutations, in the ~10 years between the first and second blood draw, five (17%) increased by >0.01 VAF, none decreased by >0.01 VAF, and 24 (83%) were unchanged. In the 22 matched sets of men (HPFS) with only one banked sample, we again observed a similar VAF for clonal mutations detected in cases (median [range] VAF: 0.0020 [0.0002-0.3280]) and controls (median [range] VAF: 0.0014 [0.0002-0.3513]; Figure 2B ).
In exploratory case-only analyses (see Online Supplementary Methods), the VAF for the most abundant clone observed at the first blood draw (i.e., the largest VAF observed at collection one) did not correlate to the time to diagnosis of AML (partial Spearman r = -0.11, p=0.55, adjusted for age and sex; Figure 3A ). In the NHS cases with a second collection blood sample, the maximum VAF in the second time point and time to AML diagnosis was not correlated (partial Spearman r=0.34, p=0.33, adjusted for age; Figure 3B ). The largest change in VAF between collections with time to AML diagnosis was also not correlated (partial Spearman r=0.30, p=0.39, adjusted for age; Figure 3C ).
Discussion
In this study, we investigated associations of clonal hematopoiesis with long-term risk of AML, leveraging ECSdetermined clonal variants and up to 22 years of follow-up after blood draw in 34 matched case-control sets from the NHS and HPFS. Surprisingly, we found no clear differences in clonal mutation abundance, location or VAF between cases and controls. As expected, DNMT3A and TET2 were the genes with the most frequently detected clonal mutations in both cases and controls 2, 6, 14 , and overall, cases and controls showed abundant mutation across the rest of the coding sequence. Few individual variants occurred frequently enough for separate analysis of AML risk, but among those occurring in at least four participants, DNMT3A R882H/C had a strong association with AML risk. We also observed statistically significant associations with AML risk for individuals with any variant with a VAF ≥ 0.01. Contrary to expectation, in the 11 matched sets with two banked blood samples, we did not observe a signature of clonal evolution over time that distinguished cases from controls or predicted latency to AML diagnosis in the cases.
Two recent studies reported findings for clonal hematopoiesis and future risk of AML 4, 5 . Briefly, both studies observed an increased risk of AML for increasing numbers of clonal mutations, higher VAF and detection or number of mutations in known driver genes. Of note, Abelson and colleagues 5 observed an increased AML risk for individuals with clones of VAF ≥ 0.005 detected by ECS, and Desai et al. 4 reported an increased risk of AML for women with clones of VAF ≥ 0.01 detected by targeted deep sequencing. We detected an increase in AML risk for persons with clonal mutations at ≥ 0.01 VAF and those with DNMT3A R882 mutations, and our observed effect estimates had a similar magnitude and precision as those reported by the previous studies. Other prior studies reported that these mutations raise AML risk by 0.5-1%/year 2,3 . For mutations detected at VAFs <0.01, our findings were less clear due to limited statistical precision. Additionally, in the subset of women with repeat blood samples, we did not observe clonal expansion over 10 years and found no evidence among the AML cases that the most abundant clone at either an early or late time point, or the largest difference in VAF between time points for any clone, correlated with time to AML onset. Similarly, neither of the previous studies observed differences in clonal expansion in individuals with serial samples who did or did not eventually develop AML 4, 5 . However, Desai and colleagues 4 observed striking differences in time to AML diagnosis for individuals with any baseline mutation and noted that the degree of diminished latency varied by mutation and clonal complexity. With our smaller sample size, we lacked resolution to perform as detailed an analysis of mutational complexity of clonal hematopoiesis, or of temporal changes, as the prior larger studies. Nonetheless, our findings extended, by several years, the pre-diagnosis period during which detection of clonal hematopoiesis could be informative for identifying individuals at an increased risk for AML.
Notably, we observed relatively similar VAFs of clonal hematopoietic mutations in cases and controls, whereas the Abelson and Desai studies 4,5 reported more striking differences in the overall VAF and mutational complexity of CHIP in cases and controls. The explanation for these discrepancies is not immediately clear, although differences in methodology for control matching or differing average lengths of follow-up across the three studies may have contributed. In the present study, we did not have sufficient sample size to compare mutational profiles of cases vs. controls within more proximal and more distal follow-up periods, but it is plausible that contrasts in clonal hematopoiesis profiles between individuals who do and do not progress may deepen as diagnosis of malignancy approaches.
Our observation of an increased risk of AML in individuals with variants at the DNMT3A R882 locus is unsurprising, given the prevalence of DNMT3A R882 hotspot mutations in AML 15 , but also highlights that different mutations in the same gene do not convey the same risk and should not be viewed as equivalent a priori. Of interest, one of the few other individual variants that occurred relatively frequently in the present study sample, DNMT3A W860R, occurred more commonly in controls than in cases. This raises the question as to whether the aggregation of variable mutations across any single gene is appropriate to evaluate true AML risk. Larger studies with sufficient statistical power to examine individual mutations at varying VAFs (and, perhaps, combinations of individual variants) may prove informative for further refining the interpretation of clonal hematopoiesis for stratifying risk of AML.
The strengths of this research include studying two large, well-characterized population-based cohorts with many years of follow-up after blood collection. We matched cases and controls carefully on potential confounding variables including age, ethnicity, sex, and date(s) of blood collection and utilized conditional logistic regression for efficient control of confounding by those variables in the analysis. Further, for a subset of women in the NHS, we explored and compared temporal changes in clonal hematopoiesis over a ~10-year interval in those who did or did not subsequently develop AML. We conducted ECS assays and ddPCR validation in a blinded manner and observed strong reproducibility of variant calls across orthogonal platforms, affirming the credibility of variants detected at very low VAFs.
The most notable limitations of the study relate to sample size and statistical precision, as previously noted. We had insufficient statistical power for concurrent interrogation of multiple mutations and for more than exploratory analysis of clone size and time to AML diagnosis. Likewise, we could not control for potential confounding variables (other than matching factors), such as BMI or history of cigarette smoking 10, 12 , or stratify by those variables or by follow-up time. Additionally, myeloproliferative neoplasms and myelodysplastic syndrome were not routinely reported in the NHS and HPFS, so we were unable to identify which participants had clonal hematopoiesis attributable to one of these pre-malignant disorders. Further, we did not have access to AML diagnostic samples for the cases in this study, making it impossible to determine which, if any, clonal hematopoietic mutations detected prior to diagnosis appeared in the founding AML clone. The study was limited technically by the sequencing panel, which targeted 54 genes recurrently mutated in AML. Future studies should expand the panel to target the entire exome or at least include additional genes that have been observed in CHIP, such as PPM1D 1 , to more fully characterize the spectrum of mutations in clonal hematopoiesis. However, any increase in panel size must be balanced with the cost of sequencing, which is higher for ECS compared to conventional NGS. Lastly, ECS, while precise, cannot co-localize mutations within the same cell. Future single-cell sequencing studies would provide further insights into the evolution of preleukemic clones and potentially improve screening for risk of developing AML.
In summary, we demonstrated that detection of AML-associated variants at VAFs as low as 0.01 is associated with long-term risk of AML in concordance with other recent reports. Additionally, our study has extended by several years the period of follow-up over which this increased risk applies and provided evidence that even individual variants in known driver genes may be associated with AML risk, suggesting that not all clonal somatic variants have equivalent associations with AML. The collective data from this and previous reports underscore that, while clonal hematopoiesis is associated with a markedly increased long-term risk of AML, the vast majority of individuals with detectable clonal hematopoiesis will not develop AML. Likewise, further detailed investigation is needed to incorporate detection of clonal hematopoiesis into AML-risk assessment for healthy individuals. Such studies will require considerably larger populations, ideally with serial samples and sufficient sample size to analyze multiple features of clonal hematopoiesis-including individual variants, genelevel mutational profiles and temporal evolution of variant clones-as well as additional genetic, epigenetic and environmental factors that may influence the stepwise progression of healthy cells to leukemic clones. Future work will also need to incorporate single cell sequencing technology to identify, which rare clonal mutations occur in the same cells and tease out the sequence of mutation acquisition driving the transformation from clonal hematopoiesis to AML.
Funding
This project was supported in part by the National Institutes of Health (R01 CA211711, UM1 CA186107, P01 CA87969, R01 CA49449, UM1 CA167552 and R01 CA149445), the Children's Discovery Institute of Washington University and St Louis Children's Hospital (MC-II-2015-461), and Hyundai Hope on Wheels (2015Q3-3).
Author Contributions
ALY, BMB and TED designed the study. ALY performed all sequencing library preps and base calling analyses. RST performed all ddPCR validation experiments. BMB performed statistical analyses. TED funded and oversaw the project. ALY, RST, BMB and TED all wrote and edited significant portions of the manuscript, figures and tables. 
Figure Legends
Case definition and control selection
For the present study, we utilized a nested case-control design. Specifically, we ascertained cases from the NHS and HPFS "blood subcohorts," which comprise the subset of cohort members who contributed to the respective first blood collections described above. We included all blood subcohort participants with a confirmed incident diagnosis of AML (ICD-8 or -9 codes of 205.0) that occurred after blood draw in individuals with no prior history of malignancy (except non-melanoma skin cancer). We matched two controls per case among individuals with no history of cancer (other than non-melanoma skin cancer) as of the case's AML diagnosis date (i.e., the "index date"). Matching criteria included cohort (which also achieved matching by sex), race (White, African-American, Asian, other), date of birth (± 1 year), date (± 1 year) and time of day of blood draw (± 4 hours) and fasting status (<8, 8+ hours) at blood draw. For the NHS cases with a second blood collection sample, we matched among controls with a second blood sample using the same matching criteria as for first blood samples.
These protocols selected 35 cases (16 NHS, 19 HPFS) and 70 controls (32 NHS, 38 HPFS), including 12 cases and 24 controls in the NHS with two blood samples, for a total of 141 samples. After exclusion of four samples with insufficient volume, 137 samples were shipped to Washington University for ECS testing. The laboratory technician was blinded to sample case-control status but could identify specimens from the same matched set and repeat samples from the same individual, to ensure that matched set trios of samples were tested together, and to facilitate ECS protocols.
CHIP determination and validation
Library preparation. Sequencing libraries were prepared as previously described 5 . As for previous studies, the Illumina TruSight Myeloid Sequencing Panel was used for targeted capture from all or part of 54 leukemiaassociated genes (Supplementary Table 1 ). Library concentration and quality was assessed on the Agilent 2200 TapeStation and libraries were pooled into equimolar groups of six. The pooled libraries were again quantified on the TapeStation and submitted for sequencing.
Sequencing. Each pool of six individual libraries was sequenced on individual lanes of the Illumina HiSeq 3000 platform using a 300-cycle kit as specified by the manufacturer. A separate technical replicate ECS library was independently generated and sequenced from each sample to reduce false positives. Technical replicates were always sequenced on different machine runs to avoid run-specific artifacts. Approximately 5-10% of PhiX control DNA was spiked into each sequencing experiment. Each lane of the HiSeq 3000 run contained approximately 300M paired-end 146 bp reads with corresponding 16 bp unique molecular index (UMI) and 8 bp sample-specific index sequences. Sequenced reads were demultiplexed by sample-specific index allowing for at most one mismatch in the index sequence. Raw sequence reads were aligned using Bowtie 2 6 as previously described 5 .
Error Corrected Sequencing Analysis. ECS analysis of raw sequencing results was performed as previously described 5 with the exception of one modification described below. Germline variants identified by the 1000 Genomes Project (Aug 2015 release) 7 above 0.001 minor allele fraction were excluded from analysis. Likely clonal single nucleotide variants (SNV) at <0.4 VAF were reported and annotated using Annovar 8 with COSMIC version 77 9 , Ensembl version 75 (Feb 2014 release) 10 , and 1000 Genomes (Aug 2015 release) 7 databases. The amino acid substitutions were predicted based on the canonical transcript reported in COSMIC. We reported SNVs identified in both technical replicates for a given sample.
Insertions and deletions (indel) were called using VarScan2 11 as described previously 5 . Single nucleotide indels in homopolymer tracks of ≥4 nucleotides in length and occurring in repetitive elements were filtered out of the final analysis. Clonal indels (<0.4 VAF) detected in both technical replicates from a given sample were reported and annotated using Annovar 8 as described previously for rare clonal SNVs.
The only modification we made to the previously published ECS analytic approach 5 addressed the limitation that the previous approach was underpowered to detect multiple clonal SNVs co-occurring at the same position because multiple true-positives could artificially inflate the calculated position-specific error rate. This prevented the identification of rare clonal mutations above the true background error rate at that position, but below/near the estimated error rate calculated based on other co-occurring clonal SNVs at higher VAFs, resulting in false negatives at frequently mutated "hot spot" loci 5 . In the present study, to improve rare SNV identification at potential hot spots, we re-called variants from the binomial error model after removing the specific variants identified in the first iteration of analysis until a subsequent iteration revealed no additional new variants.
Droplet Digital PCR Analysis. To validate our ECS-based variant calls, we performed droplet digital PCR (ddPCR) for 61-point mutations (n=41) and indels (n=20). Droplets were generated and assayed on the QX200 droplet generator and reader (Bio-Rad), respectively, using the standard protocol 12 . All probes were designed by Bio-Rad based on MIQE guidelines for quantitative digital PCR 13 . The VAF was estimated from droplets lacking the reference allele and the Poisson-estimated number of singleton droplets as described previously 5, 14 .
Statistical Analysis
We classified participants as "positive" for a mutation if that mutation was identified by ECS in both technical replicates from one participant sample. For women with repeat blood samples in the study we also identified mutations that were present (positive) only in the second blood sample and/or in both. We combined the data from the NHS and HPFS to maximize statistical power for analysis. For mutations that were present (positive) in ≥4 participants and for selected VAF thresholds (≥0.001, ≥0.005, ≥0.01 and ≥0.02), we used conditional logistic regression, conditioning on the matched sets, to calculate odds ratios (OR) and 95% confidence intervals (CI) to estimate the relative risk of AML for detection of a given variant or VAF threshold. We analyzed two series of variables, including one in which we defined mutation status according to the variants detected in the first blood collection samples, and another series in which we defined mutation status according to variants detected in either the first or the second blood collection samples. In all models we treated the respective variant-negative group as the reference category. Sparse data precluded the evaluation of potential confounding by other AML risk factors-such as body mass index (BMI) or smoking history 15, 16 -or of heterogeneity of mutation-AML risk associations by follow-up time interval or other potential effect modifiers (such as sex, BMI or smoking history). In exploratory analyses restricted to AML cases, we generated Kaplan-Meier plots to compare time (months) to AML diagnosis for individuals with and without selected pre-diagnosis mutations and VAF thresholds. We also investigated whether clone size (specifically, the size of the most common clone at each collection) or clonal expansion over time (i.e., the largest increase in VAF, regardless of the corresponding variant, for women with two blood samples) was correlated with time to AML diagnosis, using Spearman partial correlations adjusted for age and (in relation to clone size at collection one) sex. Lastly, we conducted a sensitivity analysis omitting the few individuals with a follow-up interval of less than one year after the first blood draw (Table 1) to assess their influence on the main findings. All statistical analyses were performed with SAS version 9.3; graphical descriptive analyses were performed with R version 3.3.3 using the ggplot2 and ppcor packages 17 . All hypothesis tests were two-tailed and assumed an α-error of 0.05.
Supplementary Figure 1A . The total number of mutations found per individual, color coded by annotation. Each panel depicts a matched trio of one case and two controls. Trios with set numbers <100 are women in the Nurses' Health Study and trios numbered >100 are men in the Health Professionals Follow-up Study.
Supplementary Figure 1B . The total number of coding mutations found per individual. Each panel depicts a matched trio of one case and two controls. Trios with a set number <100 are women in the Nurses' Health Study; those with a set number >100 are men in the Health Professionals Follow-up Study.
Supplementary Figure 1C . The proportion of specific point mutations observed in cases and controls across all matched case-control trios in the study sample, color coded by annotation. Figure 2 . Figure 3 . The percentage of total alleles per case or control with exonic mutations in the respective genes, calculated across all matched case-control trios (including those with samples from both Nurses' Health Study collections) and color-coded by functional change.
Supplementary
Supplementary Figure 4A . Lollipop plot depicting the amino acid sequence of DNMT3A, the most commonly mutated gene in this study sample, with the relative location of called exonic mutation plotted for cases (above the amino acid sequence) and controls (below the amino acid sequence).
Supplementary Figure 4B . A lollipop plot depicting amino acid sequences from TET2, the second most commonly mutated gene in this study sample. Exonic mutations are scattered across the entire coding sequencing in both cases and controls.
Supplementary Figure 5A . Time to acute myeloid leukemia (AML) diagnosis by pre-diagnosis DNMT3A R882H/C mutation status at one or both blood collections in Nurses' Health Study and Health Professionals Follow-up Study participants (AML cases only).
Supplementary Figure 5B . Time to acute myeloid leukemia (AML) diagnosis by pre-diagnosis detection of one or more mutations with an average variant allele fraction (VAF) of 0.005 or greater at one or both blood collections in Nurses' Health Study and Health Professionals Follow-up Study participants (AML cases only).
Supplementary Figure 5C . Time to AML diagnosis by pre-diagnosis detection of one or more mutations with an average variant allele fraction (VAF) of 0.01 or greater at one or both blood collections in Nurses' Health Study NHS and Health Professionals Follow-up Study participants (AML cases only).
Supplementary Figure 5D . Time to AML diagnosis by pre-diagnosis detection of one or more mutations with an average variant allele fraction (VAF) of 0.02 or greater at one or both blood collections in Nurses' Health Study NHS and Health Professionals Follow-up Study participants (AML cases only). C  T  TET2  exonic  Q916X  COSM43417  0.0058   25  13  Case  2  25457242  C  T  DNMT3A  exonic  R882H  COSM52944  0.0025   25  13  Case  2  25463286  C  T  DNMT3A  exonic  R736H  COSM133737  0.0034   25  13  Case  2  25466797  C  G  DNMT3A  exonic  V636L  NA  0.0020   25   13  Case  2  25466824   GGACA  GGTGG  GTAAA  CCTTT  -DNMT3A  exonic  P620fs  NA  0.0045   25  13  Case  20  31024062  G  A  ASXL1  exonic  E1183K  NA  0.0012   25  13  Case  3  38182641  T  C  MYD88  exonic  X205R  COSM85940  0.0043 0.0033   25  13  Case  4  106164053  A  T  TET2  exonic  K1158X  NA  0.0011   25  13  Case  4  106164086  T  C  TET2  splicing  NA  NA  0.0038   25  13  Case  4  106180791  T  A  TET2  exonic  C1273X A  DNMT3A  exonic  T65T  COSM4769280  0.0016   33  16  Cntl 1  4  106157105  C  A  TET2  exonic  P669Q  NA  0.0008   33  16  Cntl 1  4  106157559  T  C  TET2  exonic  S820S  NA  0.0005   33  16  Cntl 1  4  106158040   ATTAA  GGTGG  AACCT  GG  -TET2  exonic  I981fs  NA  0.0024 0.0023   33  16 Cntl 1 40  21  Cntl 2  2  25467492  G  T  DNMT3A  exonic  Y528X  NA  0.0008   40  21  Cntl 2  2  25470498  G  A  DNMT3A  exonic  R326C  COSM4169721  0.0028   40  21  Cntl 2  3  128202818  G  A  GATA2  exonic  T301I  NA  0.0011   40  21  Cntl 2  4  106156792  A  G  TET2  exonic  I565V  NA  0.0009   40  21  Cntl 2  4  106158112  A  T  TET2  exonic  K1005X Supplementary Table 3 . Droplet digital PCR (ddPCR) validation experiments for 61 clonal mutations identified in 37 individuals. There were 37 mutations detected and validated in individuals with only a single banked sample. There were 12 mutations detected in individuals with two banked samples, which were both used for ddPCR validation. The variant allele fraction (VAF) for each mutation identified by error-corrected sequencing (ECS) was reported alongside the VAF measured by ddPCR. For each identified mutation, a separate sample where that mutation was not observed by ECS was selected as a negative control. 
